



To:


The Director General of Health Services in all Governorates
Commanding Officer, Armed Forces Hospital (Al Khoudh & Salalah)
Director General of Royal Hospital
Director General of Khoula Hospital
Director General of Medical Supplies, MOH
Director General of Pvt. Health Est. (to kindly arrange distribution to all Pvt. Hospitals)
Director General of Primary Health Care, MOH
Director General of Specialised Medical Care, MOH
Director General of Quality Assurance Centre, MOH
Director General of Disease Surveillance and Control, MOH
Director of Rational Drug Use
Hospital Director (Al Nahda Hospital)
Hospital Director (Al Massara Hospital)
The Head of Medical Services in SQU Hospital
The Head of Medical Services in Royal Oman Police
The Head of Medical Services in Ministry of Defence
The Head of Medical Services in The Diwan
The Head of Medical Services in The Sultan's Special Force
The Head of Medical Services in Internal Security Services
The Head of Medical Services in Petroleum Development of Oman
The Head of Medical Services in LNG Oman
All Private Pharmacies & Drug Stores

After Compliments,

Please find attached our Circular No. 70 dated 18/04/2022
regarding **Safety update of pharmaceutical product containing Ondansetron.**

Copy to:

- Director, Office of H.E. The Undersecretary for Health Affairs
- Director of Pharmacovigilance & Drug Information Dept, DGPA&DC
- Director of Medical Device Control, DGPA&DC
- Director of Drug Control Department, DGPA&DC
- Director of Pharmaceutical Licensing Department, DGPA&DC
- Director of Central Quality Control Lab., DGPA&DC
- Section Head (Drug Information)



Circular No. 70 / 2022

16-09-1443 H
18-04-2022

سنة بثقة
Moving Forward
with Confidence



Safety update of pharmaceutical product containing Ondansetron

The Gulf Health Council has issued a drug safety alert regarding a new warning on products containing Ondansetron.

Reason for Warning:

Cases of myocardial ischemia have been reported in patients treated with ondansetron. In some patients, especially in the case of intravenous administration, symptoms appeared immediately after administration of ondansetron.

Recommendation:

1. Special warnings and precautions for use & undesirable effect as mentioned in Safety Signal Communication to be added by manufacturers in package leaflet concerning myocardial ischemia.
2. Patients should be alerted to the signs and symptoms of myocardial ischemia. Signs include: sudden chest pain or chest tightness.

Call to Report Suspected Adverse Drug Reactions

Ondansetron is registered in Oman under different trade names. The benefit-risk balance of the medicinal product(s) containing ondansetron is unchanged subject to the proposed changes to the product information and have not been withdrawn from the market.

The healthcare professionals are encouraged to report any suspected adverse drug reaction and or any drug related problem to the Department of Pharmacovigilance & Drug Information in DGPA&DC.

Dr. Mohammed Hamdan Al Rubaie
DIRECTOR GENERAL

